C4X Discovery Holdings PLC on Wednesday launched PatientSeek, a precision medicine platform for patient stratification based on genetic subgroups.
The Manchester, England-based drug discovery company credited the launch to insights gained from a successful research collaboration with the Garvan Institute of Medical Research in Australia.
C4XD gave Garvan Institute the genetic signatures for its PatientSeek subgroups in Parkinson’s disease, which researchers then applied to their studies.
They conducted a retrospective analysis of a failed phase three Parkinson’s clinical trial that had not reached its primary endpoint, in order to find out if a genetic subgroup of participants showed a benefit from the therapeutic.
C4XD said that, encouragingly, PatientSeek identified a subgroup that responded to the trial drug.
‘These results provide the first validation of PatientSeek’s ability to identify patient subgroups to optimise patient selection, which in turn could lead to enhanced probability of targeted success in clinical trials,’ the company told investors.
Clare Murray, senior vice president of the company’s Drug Discovery unit, added: ‘C4XD has already identified PatientSeek subgroups in immuno-inflammatory disease, and we will be exploring their application in bringing precision medicine approaches to these patient populations.’
C4XD shares were trading 0.7% higher at 17.24 pence each in London on Wednesday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.
